Sera of patients with systemic lupus erythematosus cross-neutralizes dengue viruses

Zainal N 1 , Tan KK 2 , Johari J 3 , Hussein H 4 , Wan Musa WR 5 , Hassan J 6 Show all authors , Lin YS 7 , AbuBakar S 1

Affiliations 

  • 1 Institute of Graduate Studies, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 3 Tropical Infectious Diseases Research and Education Centre (TIDREC), University of Malaya, Kuala Lumpur, Malaysia
  • 4 Subang Jaya Medical Centre, Subang Jaya, Selangor
  • 5 Department of Rheumatology, Putrajaya Hospital, Putrajaya
  • 6 Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 7 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Microbiol. Immunol., 2018 Oct;62(10):659-672.
PMID: 30259549 DOI: 10.1111/1348-0421.12652

Abstract

Dengue is the most prevalent mosquito-borne disease in Southeast Asia, where the incidence of systemic lupus erythematosus (SLE) is approximately 30 to 53 per 100,000. Severe dengue, however, is rarely reported among individuals with SLE. Here, whether sera of patients with SLE cross-neutralize dengue virus (DENV) was investigated. Serum samples were obtained from individuals with SLE who were dengue IgG and IgM serology negative. Neutralization assays were performed against the three major DENV serotypes. Of the dengue serology negative sera of individuals with SLE, 60%, 61% and 52% of the sera at 1/320 dilution showed more than 50% inhibition against dengue type-1 virus (DENV-1), DENV-2 and DENV-3, respectively. The neutralizing capacity of the sera was significantly greater against DENV-1 (P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications